Financial Daily from THE HINDU group of publications
Thursday, Aug 19, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Industry & Economy - Pharmaceuticals


NPPA to monitor prices of drugs with Rs 1-cr turnover

Our Bureau

New Delhi , Aug. 18

IN a bid to prevent the unusual price hike of essential drugs, the Government has decided to monitor the price hikes of drugs with a turnover of Rs 1 crore. Currently, the National Pharmaceutical Pricing Authority (NPPA) monitors the prices of drugs that have a turnover of Rs 4 crore and above.

Under this new initiative, the Government will keep an eye on almost 80 per cent of the pharmaceutical market.

Speaking to presspersons after a meeting of the State Health and Finance Ministers, the Union Chemicals and Fertilisers Minister, Mr Ram Vilas Paswan, said, "Monitoring of prices does not mean that we are controlling them. We do not want to regulate prices or curb competition."

He added that while all the States wanted to make drugs affordable to everybody, representatives favoured the idea of controlling prices.

But on the issue of having a uniform sales tax, the States felt that the Empowered Committee to look into value-added tax (VAT) should decide on drugs as well. The Minister had asked the States to exempt them from local taxes or at least advance the implementation of VAT regime for drugs.

Mr Paswan also added that the consumer is bearing the burden of the huge margins being paid by pharmaceutical companies to traders. In the case of one particular drug, it was found that while the retailer was selling the pack at Rs 26; the cost of manufacturing was less than Re 1. He favoured printing both the manufacturing cost and the retail price on the medicine strip along with the expiry date.

The Ministry has already set up a committee under the Joint Secretary with representatives from the Health and Law Ministries to look into the issue of prices. A list of essential medicines is being prepared and the committee is expected to submit its report by October. Concern has also been expressed on the issue of spurious drugs flooding the market and the need for immediate action to curb this menace.

More Stories on : Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Tiruchi Corporation to generate power from waste


Maharashtra, richest State
FIEO healthcare team leaves for S-E Asia
Human trials for Ranbaxy-MMV malaria drug soon
Apollo Hospitals holds demonstration of pranic healing
Award for LV Prasad Eye Institute
Board-level appointments in PSUs — CVC dismayed at lack of `sanctity' to its clearance
Duties on petrol, diesel cut — Consumers spared of price hike
What the reductions mean
Petronet seeks sops for Kochi LNG project
NPPA to monitor prices of drugs with Rs 1-cr turnover
`Power cos can gain from microwave technology'
Plea against KSEB unbundling
VAT panel chief meets Chidambaram
Revised DEPB rates on marine products in abeyance
`Indian textile industry less cost competitive than China, Brazil'
Call for exclusive SSI policy
Logo invited for rainwater harvesting campaign
MSOs withdraw cable strike citing Olympics
Course in animation
Coke, Pepsi hike prices by a rupee in select markets
Ministry pulled up for delay in drafting new food law
German nanotech cos looking for tie-ups in India
CII alliance to check piracy, counterfeiting
Govt to wait for CAG report on Centaur deal: Chidambaram
Microsoft tech initiative to empower women
`Extend micro-finance to rural areas'
2-day convention on gold from tomorrow
Delhi to host meet on consulting services
CII-AP to hold HR programme
Expo on garment technology in Bangalore
IOB gold card for exporters
Mills seek total ban on wheat exports
Kerala CM to discuss calamity relief with Pawar
New Ayurvedic treatment centre gaining popularity in Coimbatore
`Sagara Rani' ready for backwater cruises
Hong Kong eyeing Bollywood films to promote tourism
`Payasamela' from Aug 23



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line